SDGR Stock Recent News

Regional Banks have all the characteristics of Schrodinger's Cat. They appear phenomenally cheap on current earnings. They are dead in the water when you price in a reasonable cost of funds.

Schrodinger, Inc. (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

A Deloitte report about artificial intelligence (AI) in the life sciences puts it bluntly. Big data is the new currency for biopharma firms.

Despite a slight drop in software sales in 1Q23, attributed to timing issues with multi-year agreements, management revised guidance positively. I am optimistic about the software platform in the latter half of the year when multi-year contracts are up for renewal and new partnerships may arise.

Artificial intelligence is becoming an important value-add for collaborations. Some companies are pursuing collaboration-targeted business models.

A few recent news stories highlight the tremendous power of artificial intelligence to improve our world and boost business performance. A doctor says that the technology can be a key means of enabling healthcare to become more personalized and making diagnoses earlier.

Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of $1.36. This compares to loss of $0.48 per share a year ago.

Artificial intelligence (AI) is a powerful technology that will enable many businesses to both save money and accelerate growth. As a result, demand for powerful, efficient AI tools is likely to explode, and companies that can deliver them will be quite prosperous.

Today, we put Schrodinger, Inc. in the spotlight as we do a post fourth quarter results assessment on this intriguing developmental and software concern. The company's core software business continues to deliver steady sales growth, while Schrodinger continues to advance an intriguing early stage pipeline.

Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117 in January 2021. Schrodinger's artificial intelligence (AI) powered software technology platform utilizes physics-based modeling and sophisticated machine learning algorithms to help clients identify the suitable molecules to treat the desired ailments.